#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2 .
1-1	0-1	2	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Oxidative Modification of rRNA
2-1	4-13	Oxidative	person|abstract[3]	new|new[3]	coref|coref	6-17|6-17
2-2	14-26	Modification	abstract[3]	new[3]	_	_
2-3	27-29	of	abstract[3]	new[3]	_	_
2-4	30-34	rRNA	abstract[3]|abstract	new[3]|new	coref	3-1

#Text=rRNA constitutes the structural and functional core of the ribosome .
3-1	35-39	rRNA	abstract	giv	coref	10-17
3-2	40-51	constitutes	_	_	_	_
3-3	52-55	the	abstract[6]	new[6]	_	_
3-4	56-66	structural	abstract[6]	new[6]	_	_
3-5	67-70	and	abstract[6]	new[6]	_	_
3-6	71-81	functional	abstract[6]	new[6]	_	_
3-7	82-86	core	abstract[6]	new[6]	_	_
3-8	87-89	of	abstract[6]	new[6]	_	_
3-9	90-93	the	abstract[6]|object[7]	new[6]|new[7]	coref	10-2[0_7]
3-10	94-102	ribosome	abstract[6]|object[7]	new[6]|new[7]	_	_
3-11	103-104	.	_	_	_	_

#Text=ROS can affect RNA in a multitude of ways , including chemical modification of the base and sugar moieties , generation of abasic sites , and strand breaks .
4-1	105-108	ROS	substance	new	coref	12-29[86_0]
4-2	109-112	can	_	_	_	_
4-3	113-119	affect	_	_	_	_
4-4	120-123	RNA	substance	new	coref	8-10
4-5	124-126	in	_	_	_	_
4-6	127-128	a	abstract[10]	new[10]	_	_
4-7	129-138	multitude	abstract[10]	new[10]	_	_
4-8	139-141	of	abstract[10]	new[10]	_	_
4-9	142-146	ways	abstract[10]|abstract	new[10]|new	_	_
4-10	147-148	,	abstract[10]	new[10]	_	_
4-11	149-158	including	abstract[10]	new[10]	_	_
4-12	159-167	chemical	abstract[10]|abstract[12]	new[10]|new[12]	coref	22-15[176_12]
4-13	168-180	modification	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-14	181-183	of	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-15	184-187	the	abstract[10]|abstract[12]|place[13]	new[10]|new[12]|new[13]	coref	7-22[38_13]
4-16	188-192	base	abstract[10]|abstract[12]|place[13]	new[10]|new[12]|new[13]	_	_
4-17	193-196	and	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-18	197-202	sugar	abstract[10]|abstract[12]|substance|substance[15]	new[10]|new[12]|new|new[15]	_	_
4-19	203-211	moieties	abstract[10]|abstract[12]|substance[15]	new[10]|new[12]|new[15]	_	_
4-20	212-213	,	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-21	214-224	generation	abstract[10]|abstract[12]|abstract[16]	new[10]|new[12]|new[16]	_	_
4-22	225-227	of	abstract[10]|abstract[12]|abstract[16]	new[10]|new[12]|new[16]	_	_
4-23	228-234	abasic	abstract[10]|abstract[12]|abstract[16]|abstract|place[18]	new[10]|new[12]|new[16]|new|new[18]	_	_
4-24	235-240	sites	abstract[10]|abstract[12]|abstract[16]|place[18]	new[10]|new[12]|new[16]|new[18]	_	_
4-25	241-242	,	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-26	243-246	and	abstract[10]|abstract[12]	new[10]|new[12]	_	_
4-27	247-253	strand	abstract[10]|abstract[12]|place|event[20]	new[10]|new[12]|new|new[20]	_	_
4-28	254-260	breaks	abstract[10]|abstract[12]|event[20]	new[10]|new[12]|new[20]	_	_
4-29	261-262	.	_	_	_	_

#Text=Guanine is the most easily oxidized nucleobase and best studied in this respect .
5-1	263-270	Guanine	substance	new	coref	5-3[22_0]
5-2	271-273	is	_	_	_	_
5-3	274-277	the	substance[22]	giv[22]	coref	6-5[0_22]
5-4	278-282	most	substance[22]	giv[22]	_	_
5-5	283-289	easily	substance[22]	giv[22]	_	_
5-6	290-298	oxidized	substance[22]	giv[22]	_	_
5-7	299-309	nucleobase	substance[22]	giv[22]	_	_
5-8	310-313	and	_	_	_	_
5-9	314-318	best	_	_	_	_
5-10	319-326	studied	_	_	_	_
5-11	327-329	in	_	_	_	_
5-12	330-334	this	abstract[23]	new[23]	_	_
5-13	335-342	respect	abstract[23]	new[23]	_	_
5-14	343-344	.	_	_	_	_

#Text=An oxidized form of guanine , 8-oxo-7,8-dihydroguanine ( 8-hydroxyguanine ; 8-oxo-G ) , is a ubiquitous oxidative lesion , readily detectable in cellular nucleic acids .
6-1	345-347	An	abstract[24]	new[24]	coref	6-15[30_24]
6-2	348-356	oxidized	abstract[24]	new[24]	_	_
6-3	357-361	form	abstract[24]	new[24]	_	_
6-4	362-364	of	abstract[24]	new[24]	_	_
6-5	365-372	guanine	abstract[24]|substance	new[24]|giv	appos	6-7
6-6	373-374	,	_	_	_	_
6-7	375-399	8-oxo-7,8-dihydroguanine	substance	giv	appos	6-9
6-8	400-401	(	_	_	_	_
6-9	402-418	8-hydroxyguanine	substance	giv	_	_
6-10	419-420	;	_	_	_	_
6-11	421-428	8-oxo-G	abstract	new	coref	7-6
6-12	429-430	)	_	_	_	_
6-13	431-432	,	_	_	_	_
6-14	433-435	is	_	_	_	_
6-15	436-437	a	abstract[30]	giv[30]	_	_
6-16	438-448	ubiquitous	abstract[30]	giv[30]	_	_
6-17	449-458	oxidative	person|abstract[30]	giv|giv[30]	coref	13-28
6-18	459-465	lesion	abstract[30]	giv[30]	_	_
6-19	466-467	,	_	_	_	_
6-20	468-475	readily	_	_	_	_
6-21	476-486	detectable	_	_	_	_
6-22	487-489	in	_	_	_	_
6-23	490-498	cellular	substance[31]	new[31]	_	_
6-24	499-506	nucleic	substance[31]	new[31]	_	_
6-25	507-512	acids	substance[31]	new[31]	_	_
6-26	513-514	.	_	_	_	_

#Text=When present in mRNA , 8-oxo-G interferes with decoding , possibly through the formation of a Hoogsteen pair with adenine when the base rotates around the N-glycosidic bond .
7-1	515-519	When	_	_	_	_
7-2	520-527	present	_	_	_	_
7-3	528-530	in	_	_	_	_
7-4	531-535	mRNA	substance	new	_	_
7-5	536-537	,	_	_	_	_
7-6	538-545	8-oxo-G	abstract	giv	coref	9-10
7-7	546-556	interferes	_	_	_	_
7-8	557-561	with	_	_	_	_
7-9	562-570	decoding	abstract	new	_	_
7-10	571-572	,	_	_	_	_
7-11	573-581	possibly	event[35]	new[35]	_	_
7-12	582-589	through	event[35]	new[35]	_	_
7-13	590-593	the	event[35]	new[35]	_	_
7-14	594-603	formation	event[35]	new[35]	_	_
7-15	604-606	of	event[35]	new[35]	_	_
7-16	607-608	a	event[35]|plant[36]	new[35]|new[36]	_	_
7-17	609-618	Hoogsteen	event[35]|plant[36]	new[35]|new[36]	_	_
7-18	619-623	pair	event[35]|plant[36]	new[35]|new[36]	_	_
7-19	624-628	with	event[35]|plant[36]	new[35]|new[36]	_	_
7-20	629-636	adenine	event[35]|plant[36]|substance	new[35]|new[36]|new	_	_
7-21	637-641	when	_	_	_	_
7-22	642-645	the	place[38]	giv[38]	_	_
7-23	646-650	base	place[38]	giv[38]	_	_
7-24	651-658	rotates	_	_	_	_
7-25	659-665	around	_	_	_	_
7-26	666-669	the	object[40]	new[40]	_	_
7-27	670-682	N-glycosidic	person|object[40]	new|new[40]	_	_
7-28	683-687	bond	object[40]	new[40]	_	_
7-29	688-689	.	_	_	_	_

#Text=The altered base-pairing capacity of 8-oxo-G can also perturb RNA folding .
8-1	690-693	The	abstract[41]	new[41]	_	_
8-2	694-701	altered	abstract[41]	new[41]	_	_
8-3	702-714	base-pairing	abstract[41]	new[41]	_	_
8-4	715-723	capacity	abstract[41]	new[41]	_	_
8-5	724-726	of	abstract[41]	new[41]	_	_
8-6	727-734	8-oxo-G	abstract[41]|person	new[41]|new	_	_
8-7	735-738	can	_	_	_	_
8-8	739-743	also	_	_	_	_
8-9	744-751	perturb	_	_	_	_
8-10	752-755	RNA	substance|abstract[44]	giv|new[44]	coref|coref	9-15|9-15
8-11	756-763	folding	abstract[44]	new[44]	_	_
8-12	764-765	.	_	_	_	_

#Text=A recent study revealed a variety of outcomes when 8-oxo-G was incorporated into model RNA substrates , from stabilization of existing structural motifs to their destabilization and rearrangements into new structures .
9-1	766-767	A	abstract[45]	new[45]	coref	14-2[101_45]
9-2	768-774	recent	abstract[45]	new[45]	_	_
9-3	775-780	study	abstract[45]	new[45]	_	_
9-4	781-789	revealed	_	_	_	_
9-5	790-791	a	abstract[46]	new[46]	_	_
9-6	792-799	variety	abstract[46]	new[46]	_	_
9-7	800-802	of	abstract[46]	new[46]	_	_
9-8	803-811	outcomes	abstract[46]|abstract	new[46]|new	ana	9-25
9-9	812-816	when	_	_	_	_
9-10	817-824	8-oxo-G	abstract	giv	coref	14-20
9-11	825-828	was	_	_	_	_
9-12	829-841	incorporated	_	_	_	_
9-13	842-846	into	_	_	_	_
9-14	847-852	model	object[50]	new[50]	_	_
9-15	853-856	RNA	substance|object[50]	giv|new[50]	coref	12-13
9-16	857-867	substrates	object[50]	new[50]	_	_
9-17	868-869	,	_	_	_	_
9-18	870-874	from	_	_	_	_
9-19	875-888	stabilization	abstract	new	_	_
9-20	889-891	of	_	_	_	_
9-21	892-900	existing	_	_	_	_
9-22	901-911	structural	object[52]	new[52]	_	_
9-23	912-918	motifs	object[52]	new[52]	_	_
9-24	919-921	to	_	_	_	_
9-25	922-927	their	abstract|abstract[54]	giv|new[54]	_	_
9-26	928-943	destabilization	abstract[54]	new[54]	_	_
9-27	944-947	and	_	_	_	_
9-28	948-962	rearrangements	abstract[55]	new[55]	_	_
9-29	963-967	into	abstract[55]	new[55]	_	_
9-30	968-971	new	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-31	972-982	structures	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-32	983-984	.	_	_	_	_

#Text=Since ribosome activities in translation depend on many precisely tuned conformational changes and movements within its rRNA framework , oxidation of the bases that are critical for maintaining the correct rRNA structure may impair ribosome functions .
10-1	985-990	Since	_	_	_	_
10-2	991-999	ribosome	object|abstract[58]	giv|new[58]	coref|coref	10-35|10-35
10-3	1000-1010	activities	abstract[58]	new[58]	_	_
10-4	1011-1013	in	abstract[58]	new[58]	_	_
10-5	1014-1025	translation	abstract[58]|abstract	new[58]|new	ana	10-16
10-6	1026-1032	depend	_	_	_	_
10-7	1033-1035	on	_	_	_	_
10-8	1036-1040	many	abstract[60]	new[60]	_	_
10-9	1041-1050	precisely	abstract[60]	new[60]	_	_
10-10	1051-1056	tuned	abstract[60]	new[60]	_	_
10-11	1057-1071	conformational	abstract[60]	new[60]	_	_
10-12	1072-1079	changes	abstract[60]	new[60]	_	_
10-13	1080-1083	and	_	_	_	_
10-14	1084-1093	movements	abstract[61]	new[61]	_	_
10-15	1094-1100	within	abstract[61]	new[61]	_	_
10-16	1101-1104	its	abstract[61]|abstract|object[64]	new[61]|giv|new[64]	_	_
10-17	1105-1109	rRNA	abstract[61]|abstract|object[64]	new[61]|giv|new[64]	coref	10-31
10-18	1110-1119	framework	abstract[61]|object[64]	new[61]|new[64]	_	_
10-19	1120-1121	,	_	_	_	_
10-20	1122-1131	oxidation	event[65]	new[65]	coref	11-14[0_65]
10-21	1132-1134	of	event[65]	new[65]	_	_
10-22	1135-1138	the	event[65]|abstract[66]	new[65]|new[66]	_	_
10-23	1139-1144	bases	event[65]|abstract[66]	new[65]|new[66]	_	_
10-24	1145-1149	that	_	_	_	_
10-25	1150-1153	are	_	_	_	_
10-26	1154-1162	critical	_	_	_	_
10-27	1163-1166	for	_	_	_	_
10-28	1167-1178	maintaining	_	_	_	_
10-29	1179-1182	the	abstract[68]	new[68]	_	_
10-30	1183-1190	correct	abstract[68]	new[68]	_	_
10-31	1191-1195	rRNA	place|abstract[68]	giv|new[68]	coref	12-8[80_0]
10-32	1196-1205	structure	abstract[68]	new[68]	_	_
10-33	1206-1209	may	_	_	_	_
10-34	1210-1216	impair	_	_	_	_
10-35	1217-1225	ribosome	object|abstract[70]	giv|new[70]	coref|coref	11-25[77_0]|11-25[77_0]
10-36	1226-1235	functions	abstract[70]	new[70]	_	_
10-37	1236-1237	.	_	_	_	_

#Text=It seems therefore likely that the need to withstand a certain degree of oxidation was one of the forces in shaping the evolution of the ribosome .
11-1	1238-1240	It	_	_	_	_
11-2	1241-1246	seems	_	_	_	_
11-3	1247-1256	therefore	_	_	_	_
11-4	1257-1263	likely	_	_	_	_
11-5	1264-1268	that	_	_	_	_
11-6	1269-1272	the	abstract[71]	new[71]	_	_
11-7	1273-1277	need	abstract[71]	new[71]	_	_
11-8	1278-1280	to	_	_	_	_
11-9	1281-1290	withstand	_	_	_	_
11-10	1291-1292	a	abstract[72]	new[72]	_	_
11-11	1293-1300	certain	abstract[72]	new[72]	_	_
11-12	1301-1307	degree	abstract[72]	new[72]	_	_
11-13	1308-1310	of	abstract[72]	new[72]	_	_
11-14	1311-1320	oxidation	abstract[72]|event	new[72]|giv	coref	13-4[90_0]
11-15	1321-1324	was	_	_	_	_
11-16	1325-1328	one	abstract[74]	new[74]	_	_
11-17	1329-1331	of	abstract[74]	new[74]	_	_
11-18	1332-1335	the	abstract[74]|abstract[75]	new[74]|new[75]	_	_
11-19	1336-1342	forces	abstract[74]|abstract[75]	new[74]|new[75]	_	_
11-20	1343-1345	in	_	_	_	_
11-21	1346-1353	shaping	_	_	_	_
11-22	1354-1357	the	abstract[76]	new[76]	_	_
11-23	1358-1367	evolution	abstract[76]	new[76]	_	_
11-24	1368-1370	of	abstract[76]	new[76]	_	_
11-25	1371-1374	the	abstract[76]|object[77]	new[76]|giv[77]	_	_
11-26	1375-1383	ribosome	abstract[76]|object[77]	new[76]|giv[77]	_	_
11-27	1384-1385	.	_	_	_	_

#Text=A striking disappearance of many guanines from mitochondrial rRNA and reduced overall RNA content may be two such evolutionary adaptations that “ hardened ” mitoribosomes against damage from the abundant ROS generated inside mitochondria .
12-1	1386-1387	A	abstract[78]	new[78]	_	_
12-2	1388-1396	striking	abstract[78]	new[78]	_	_
12-3	1397-1410	disappearance	abstract[78]	new[78]	_	_
12-4	1411-1413	of	abstract[78]	new[78]	_	_
12-5	1414-1418	many	abstract[78]|substance[79]	new[78]|new[79]	_	_
12-6	1419-1427	guanines	abstract[78]|substance[79]	new[78]|new[79]	_	_
12-7	1428-1432	from	abstract[78]|substance[79]	new[78]|new[79]	_	_
12-8	1433-1446	mitochondrial	abstract[78]|substance[79]|abstract[80]	new[78]|new[79]|giv[80]	coref	14-28[0_80]
12-9	1447-1451	rRNA	abstract[78]|substance[79]|abstract[80]	new[78]|new[79]|giv[80]	_	_
12-10	1452-1455	and	_	_	_	_
12-11	1456-1463	reduced	abstract[82]	new[82]	coref	12-17[83_82]
12-12	1464-1471	overall	abstract[82]	new[82]	_	_
12-13	1472-1475	RNA	substance|abstract[82]	giv|new[82]	coref	13-5
12-14	1476-1483	content	abstract[82]	new[82]	_	_
12-15	1484-1487	may	_	_	_	_
12-16	1488-1490	be	_	_	_	_
12-17	1491-1494	two	abstract[83]	giv[83]	coref	18-1[132_83]
12-18	1495-1499	such	abstract[83]	giv[83]	_	_
12-19	1500-1512	evolutionary	abstract[83]	giv[83]	_	_
12-20	1513-1524	adaptations	abstract[83]	giv[83]	_	_
12-21	1525-1529	that	_	_	_	_
12-22	1530-1531	“	_	_	_	_
12-23	1532-1540	hardened	_	_	_	_
12-24	1541-1542	”	_	_	_	_
12-25	1543-1556	mitoribosomes	object[84]	new[84]	_	_
12-26	1557-1564	against	object[84]	new[84]	_	_
12-27	1565-1571	damage	object[84]|abstract[85]	new[84]|new[85]	coref	13-27[96_85]
12-28	1572-1576	from	object[84]|abstract[85]	new[84]|new[85]	_	_
12-29	1577-1580	the	object[84]|abstract[85]|substance[86]	new[84]|new[85]|giv[86]	_	_
12-30	1581-1589	abundant	object[84]|abstract[85]|substance[86]	new[84]|new[85]|giv[86]	_	_
12-31	1590-1593	ROS	object[84]|abstract[85]|substance[86]	new[84]|new[85]|giv[86]	_	_
12-32	1594-1603	generated	_	_	_	_
12-33	1604-1610	inside	_	_	_	_
12-34	1611-1623	mitochondria	object	new	_	_
12-35	1624-1625	.	_	_	_	_

#Text=The extent of cellular RNA oxidation was reported to exceed that of DNA when cells were directly treated with H2O2 or subjected to conditions that induce secondary oxidative damage , such as UVA irradiation and ammonia overload .
13-1	1626-1629	The	abstract[88]	new[88]	_	_
13-2	1630-1636	extent	abstract[88]	new[88]	_	_
13-3	1637-1639	of	abstract[88]	new[88]	_	_
13-4	1640-1648	cellular	abstract[88]|event[90]	new[88]|giv[90]	_	_
13-5	1649-1652	RNA	abstract[88]|substance|event[90]	new[88]|giv|giv[90]	coref	14-24
13-6	1653-1662	oxidation	abstract[88]|event[90]	new[88]|giv[90]	_	_
13-7	1663-1666	was	_	_	_	_
13-8	1667-1675	reported	_	_	_	_
13-9	1676-1678	to	_	_	_	_
13-10	1679-1685	exceed	_	_	_	_
13-11	1686-1690	that	_	_	_	_
13-12	1691-1693	of	_	_	_	_
13-13	1694-1697	DNA	substance	new	_	_
13-14	1698-1702	when	_	_	_	_
13-15	1703-1708	cells	object	new	coref	14-7[103_0]
13-16	1709-1713	were	_	_	_	_
13-17	1714-1722	directly	_	_	_	_
13-18	1723-1730	treated	_	_	_	_
13-19	1731-1735	with	_	_	_	_
13-20	1736-1740	H2O2	substance	new	coref	14-11
13-21	1741-1743	or	_	_	_	_
13-22	1744-1753	subjected	_	_	_	_
13-23	1754-1756	to	_	_	_	_
13-24	1757-1767	conditions	abstract	new	coref	21-52[171_0]
13-25	1768-1772	that	_	_	_	_
13-26	1773-1779	induce	_	_	_	_
13-27	1780-1789	secondary	abstract[96]	giv[96]	coref	15-32[120_96]
13-28	1790-1799	oxidative	event|abstract[96]	giv|giv[96]	coref	15-32
13-29	1800-1806	damage	abstract[96]	giv[96]	_	_
13-30	1807-1808	,	abstract[96]	giv[96]	_	_
13-31	1809-1813	such	abstract[96]	giv[96]	_	_
13-32	1814-1816	as	abstract[96]	giv[96]	_	_
13-33	1817-1820	UVA	abstract[96]|place|substance[98]	giv[96]|new|new[98]	_	_
13-34	1821-1832	irradiation	abstract[96]|substance[98]	giv[96]|new[98]	_	_
13-35	1833-1836	and	abstract[96]	giv[96]	_	_
13-36	1837-1844	ammonia	abstract[96]|substance|quantity[100]	giv[96]|new|new[100]	_	_
13-37	1845-1853	overload	abstract[96]|quantity[100]	giv[96]|new[100]	_	_
13-38	1854-1855	.	_	_	_	_

#Text=In one study , exposure of E. coli cells to H2O2 was shown to induce a dosage-dependent increase of 8-oxo-G in all tested RNA types , including rRNA .
14-1	1856-1858	In	_	_	_	_
14-2	1859-1862	one	abstract[101]	giv[101]	coref	15-19[116_101]
14-3	1863-1868	study	abstract[101]	giv[101]	_	_
14-4	1869-1870	,	_	_	_	_
14-5	1871-1879	exposure	event[102]	new[102]	_	_
14-6	1880-1882	of	event[102]	new[102]	_	_
14-7	1883-1885	E.	event[102]|object[103]	new[102]|giv[103]	coref	16-20[126_103]
14-8	1886-1890	coli	event[102]|object[103]	new[102]|giv[103]	_	_
14-9	1891-1896	cells	event[102]|object[103]	new[102]|giv[103]	_	_
14-10	1897-1899	to	event[102]|object[103]	new[102]|giv[103]	_	_
14-11	1900-1904	H2O2	event[102]|object[103]|substance	new[102]|giv[103]|giv	coref	15-8
14-12	1905-1908	was	_	_	_	_
14-13	1909-1914	shown	_	_	_	_
14-14	1915-1917	to	_	_	_	_
14-15	1918-1924	induce	_	_	_	_
14-16	1925-1926	a	abstract[105]	new[105]	_	_
14-17	1927-1943	dosage-dependent	abstract[105]	new[105]	_	_
14-18	1944-1952	increase	abstract[105]	new[105]	_	_
14-19	1953-1955	of	abstract[105]	new[105]	_	_
14-20	1956-1963	8-oxo-G	abstract[105]|quantity	new[105]|giv	coref	19-4[149_0]
14-21	1964-1966	in	_	_	_	_
14-22	1967-1970	all	place[108]	new[108]	_	_
14-23	1971-1977	tested	place[108]	new[108]	_	_
14-24	1978-1981	RNA	abstract|place[108]	giv|new[108]	coref	16-17[125_0]
14-25	1982-1987	types	place[108]	new[108]	_	_
14-26	1988-1989	,	place[108]	new[108]	_	_
14-27	1990-1999	including	place[108]	new[108]	_	_
14-28	2000-2004	rRNA	place[108]|abstract	new[108]|giv	coref	15-26
14-29	2005-2006	.	_	_	_	_

#Text=By comparing 8-oxo-G levels after in vitro H2O2 treatment of RNAs in their native and denatured forms , the same study concluded that folding of rRNA did not protect it against oxidative damage .
15-1	2007-2009	By	_	_	_	_
15-2	2010-2019	comparing	_	_	_	_
15-3	2020-2027	8-oxo-G	abstract[110]	new[110]	coref	19-1[148_110]
15-4	2028-2034	levels	abstract[110]	new[110]	_	_
15-5	2035-2040	after	_	_	_	_
15-6	2041-2043	in	_	_	_	_
15-7	2044-2049	vitro	event[112]	new[112]	_	_
15-8	2050-2054	H2O2	abstract|event[112]	giv|new[112]	_	_
15-9	2055-2064	treatment	event[112]	new[112]	_	_
15-10	2065-2067	of	event[112]	new[112]	_	_
15-11	2068-2072	RNAs	event[112]|substance	new[112]|new	ana	15-13
15-12	2073-2075	in	_	_	_	_
15-13	2076-2081	their	substance|abstract[115]	giv|new[115]	_	_
15-14	2082-2088	native	abstract[115]	new[115]	_	_
15-15	2089-2092	and	abstract[115]	new[115]	_	_
15-16	2093-2102	denatured	abstract[115]	new[115]	_	_
15-17	2103-2108	forms	abstract[115]	new[115]	_	_
15-18	2109-2110	,	_	_	_	_
15-19	2111-2114	the	abstract[116]	giv[116]	_	_
15-20	2115-2119	same	abstract[116]	giv[116]	_	_
15-21	2120-2125	study	abstract[116]	giv[116]	_	_
15-22	2126-2135	concluded	_	_	_	_
15-23	2136-2140	that	_	_	_	_
15-24	2141-2148	folding	_	_	_	_
15-25	2149-2151	of	_	_	_	_
15-26	2152-2156	rRNA	abstract	giv	ana	15-30
15-27	2157-2160	did	_	_	_	_
15-28	2161-2164	not	_	_	_	_
15-29	2165-2172	protect	_	_	_	_
15-30	2173-2175	it	abstract	giv	coref	21-19
15-31	2176-2183	against	_	_	_	_
15-32	2184-2193	oxidative	event|abstract[120]	giv|giv[120]	coref|coref	21-47[169_120]|21-47[169_120]
15-33	2194-2200	damage	abstract[120]	giv[120]	_	_
15-34	2201-2202	.	_	_	_	_

#Text=Similar conclusions were made by Willi and colleagues , who used an 8-oxo-G antibody to immunoprecipitate oxidized RNA from H2O2-treated E. coli cells .
16-1	2203-2210	Similar	abstract[121]	new[121]	_	_
16-2	2211-2222	conclusions	abstract[121]	new[121]	_	_
16-3	2223-2227	were	_	_	_	_
16-4	2228-2232	made	_	_	_	_
16-5	2233-2235	by	_	_	_	_
16-6	2236-2241	Willi	person	new	_	_
16-7	2242-2245	and	_	_	_	_
16-8	2246-2256	colleagues	person	new	_	_
16-9	2257-2258	,	_	_	_	_
16-10	2259-2262	who	_	_	_	_
16-11	2263-2267	used	_	_	_	_
16-12	2268-2270	an	object[124]	new[124]	_	_
16-13	2271-2278	8-oxo-G	object[124]	new[124]	_	_
16-14	2279-2287	antibody	object[124]	new[124]	_	_
16-15	2288-2290	to	_	_	_	_
16-16	2291-2308	immunoprecipitate	_	_	_	_
16-17	2309-2317	oxidized	substance[125]	giv[125]	coref	17-11[130_125]
16-18	2318-2321	RNA	substance[125]	giv[125]	_	_
16-19	2322-2326	from	_	_	_	_
16-20	2327-2339	H2O2-treated	object[126]	giv[126]	_	_
16-21	2340-2342	E.	object[126]	giv[126]	_	_
16-22	2343-2347	coli	object[126]	giv[126]	_	_
16-23	2348-2353	cells	object[126]	giv[126]	_	_
16-24	2354-2355	.	_	_	_	_

#Text=A large body of observations points to the association of oxidized RNA with disease .
17-1	2356-2357	A	object[127]	new[127]	coref	18-38[0_127]
17-2	2358-2363	large	object[127]	new[127]	_	_
17-3	2364-2368	body	object[127]	new[127]	_	_
17-4	2369-2371	of	object[127]	new[127]	_	_
17-5	2372-2384	observations	object[127]|abstract	new[127]|new	_	_
17-6	2385-2391	points	_	_	_	_
17-7	2392-2394	to	_	_	_	_
17-8	2395-2398	the	abstract[129]	new[129]	_	_
17-9	2399-2410	association	abstract[129]	new[129]	_	_
17-10	2411-2413	of	abstract[129]	new[129]	_	_
17-11	2414-2422	oxidized	abstract[129]|substance[130]	new[129]|giv[130]	coref	18-7[134_130]
17-12	2423-2426	RNA	abstract[129]|substance[130]	new[129]|giv[130]	_	_
17-13	2427-2431	with	abstract[129]|substance[130]	new[129]|giv[130]	_	_
17-14	2432-2439	disease	abstract[129]|substance[130]|abstract	new[129]|giv[130]|new	coref	18-15[137_0]
17-15	2440-2441	.	_	_	_	_

#Text=High 8-oxo-G content in cytoplasmic and nucleolar RNA was found in vulnerable neurons in Alzheimer′s disease ( AD ) , Parkinson ’s disease , and neurons of the hippocampal region and temporal neocortex in patients with Lewy body dementia .
18-1	2442-2446	High	abstract[132]	giv[132]	_	_
18-2	2447-2454	8-oxo-G	abstract[132]	giv[132]	_	_
18-3	2455-2462	content	abstract[132]	giv[132]	_	_
18-4	2463-2465	in	abstract[132]	giv[132]	_	_
18-5	2466-2477	cytoplasmic	abstract[132]|abstract	giv[132]|new	_	_
18-6	2478-2481	and	abstract[132]	giv[132]	_	_
18-7	2482-2491	nucleolar	abstract[132]|substance[134]	giv[132]|giv[134]	coref	19-6[0_134]
18-8	2492-2495	RNA	abstract[132]|substance[134]	giv[132]|giv[134]	_	_
18-9	2496-2499	was	_	_	_	_
18-10	2500-2505	found	_	_	_	_
18-11	2506-2508	in	_	_	_	_
18-12	2509-2519	vulnerable	place[135]	new[135]	_	_
18-13	2520-2527	neurons	place[135]	new[135]	_	_
18-14	2528-2530	in	place[135]	new[135]	_	_
18-15	2531-2542	Alzheimer′s	place[135]|place|abstract[137]	new[135]|new|giv[137]	appos|appos	18-18[0_137]|18-18[0_137]
18-16	2543-2550	disease	place[135]|abstract[137]	new[135]|giv[137]	_	_
18-17	2551-2552	(	_	_	_	_
18-18	2553-2555	AD	abstract	giv	coref	18-21[140_0]
18-19	2556-2557	)	_	_	_	_
18-20	2558-2559	,	_	_	_	_
18-21	2560-2569	Parkinson	person[139]|abstract[140]	new[139]|giv[140]	coref|coref	22-21[0_140]|22-21[0_140]
18-22	2570-2572	’s	person[139]|abstract[140]	new[139]|giv[140]	_	_
18-23	2573-2580	disease	abstract[140]	giv[140]	_	_
18-24	2581-2582	,	_	_	_	_
18-25	2583-2586	and	_	_	_	_
18-26	2587-2594	neurons	place[141]	new[141]	_	_
18-27	2595-2597	of	place[141]	new[141]	_	_
18-28	2598-2601	the	place[141]|place[142]	new[141]|new[142]	_	_
18-29	2602-2613	hippocampal	place[141]|place[142]	new[141]|new[142]	_	_
18-30	2614-2620	region	place[141]|place[142]	new[141]|new[142]	_	_
18-31	2621-2624	and	place[141]	new[141]	_	_
18-32	2625-2633	temporal	place[141]|abstract[143]	new[141]|new[143]	_	_
18-33	2634-2643	neocortex	place[141]|abstract[143]	new[141]|new[143]	_	_
18-34	2644-2646	in	place[141]|abstract[143]	new[141]|new[143]	_	_
18-35	2647-2655	patients	place[141]|abstract[143]|person[144]	new[141]|new[143]|new[144]	coref	22-19[177_144]
18-36	2656-2660	with	place[141]|abstract[143]|person[144]	new[141]|new[143]|new[144]	_	_
18-37	2661-2665	Lewy	place[141]|abstract[143]|person[144]|person|abstract[147]	new[141]|new[143]|new[144]|new|new[147]	_	_
18-38	2666-2670	body	place[141]|abstract[143]|person[144]|object|abstract[147]	new[141]|new[143]|new[144]|giv|new[147]	_	_
18-39	2671-2679	dementia	place[141]|abstract[143]|person[144]|abstract[147]	new[141]|new[143]|new[144]|new[147]	_	_
18-40	2680-2681	.	_	_	_	_

#Text=Elevated levels of 8-oxo-G in RNA were also detected in neuropsychiatric disorders , including schizophrenia , depressive , and bipolar disorders .
19-1	2682-2690	Elevated	abstract[148]	giv[148]	_	_
19-2	2691-2697	levels	abstract[148]	giv[148]	_	_
19-3	2698-2700	of	abstract[148]	giv[148]	_	_
19-4	2701-2708	8-oxo-G	abstract[148]|abstract[149]	giv[148]|giv[149]	coref	20-12[0_149]
19-5	2709-2711	in	abstract[148]|abstract[149]	giv[148]|giv[149]	_	_
19-6	2712-2715	RNA	abstract[148]|abstract[149]|substance	giv[148]|giv[149]|giv	coref	20-3
19-7	2716-2720	were	_	_	_	_
19-8	2721-2725	also	_	_	_	_
19-9	2726-2734	detected	_	_	_	_
19-10	2735-2737	in	_	_	_	_
19-11	2738-2754	neuropsychiatric	abstract[151]	new[151]	_	_
19-12	2755-2764	disorders	abstract[151]	new[151]	_	_
19-13	2765-2766	,	abstract[151]	new[151]	_	_
19-14	2767-2776	including	abstract[151]	new[151]	_	_
19-15	2777-2790	schizophrenia	abstract[151]|abstract	new[151]|new	_	_
19-16	2791-2792	,	abstract[151]	new[151]	_	_
19-17	2793-2803	depressive	abstract[151]|abstract	new[151]|new	_	_
19-18	2804-2805	,	abstract[151]	new[151]	_	_
19-19	2806-2809	and	abstract[151]	new[151]	_	_
19-20	2810-2817	bipolar	abstract[151]|abstract[154]	new[151]|new[154]	_	_
19-21	2818-2827	disorders	abstract[151]|abstract[154]	new[151]|new[154]	_	_
19-22	2828-2829	.	_	_	_	_

#Text=Furthermore , RNA extracted from atherosclerotic plaques was heavily modified with 8-oxo-G .
20-1	2830-2841	Furthermore	_	_	_	_
20-2	2842-2843	,	_	_	_	_
20-3	2844-2847	RNA	substance	giv	coref	21-16[162_0]
20-4	2848-2857	extracted	_	_	_	_
20-5	2858-2862	from	_	_	_	_
20-6	2863-2878	atherosclerotic	substance|object[157]	new|new[157]	_	_
20-7	2879-2886	plaques	object[157]	new[157]	_	_
20-8	2887-2890	was	_	_	_	_
20-9	2891-2898	heavily	_	_	_	_
20-10	2899-2907	modified	_	_	_	_
20-11	2908-2912	with	_	_	_	_
20-12	2913-2920	8-oxo-G	substance	giv	_	_
20-13	2921-2922	.	_	_	_	_

#Text=Although links between 8-oxo-G and human pathologies have been based largely on the analysis of total RNA , rRNA is the most abundant cellular RNA type , which typically accounts for about 80 % of the total RNA , from which one can reasonably assume that oxidative damage to ribosomes in all these pathological conditions must be widespread .
21-1	2923-2931	Although	_	_	_	_
21-2	2932-2937	links	abstract[159]	new[159]	_	_
21-3	2938-2945	between	abstract[159]	new[159]	_	_
21-4	2946-2953	8-oxo-G	abstract[159]|abstract[160]	new[159]|new[160]	_	_
21-5	2954-2957	and	abstract[159]|abstract[160]	new[159]|new[160]	_	_
21-6	2958-2963	human	abstract[159]|abstract[160]	new[159]|new[160]	_	_
21-7	2964-2975	pathologies	abstract[159]|abstract[160]	new[159]|new[160]	_	_
21-8	2976-2980	have	_	_	_	_
21-9	2981-2985	been	_	_	_	_
21-10	2986-2991	based	_	_	_	_
21-11	2992-2999	largely	_	_	_	_
21-12	3000-3002	on	_	_	_	_
21-13	3003-3006	the	abstract[161]	new[161]	_	_
21-14	3007-3015	analysis	abstract[161]	new[161]	_	_
21-15	3016-3018	of	abstract[161]	new[161]	_	_
21-16	3019-3024	total	abstract[161]|substance[162]	new[161]|giv[162]	coref	21-25[0_162]
21-17	3025-3028	RNA	abstract[161]|substance[162]	new[161]|giv[162]	_	_
21-18	3029-3030	,	_	_	_	_
21-19	3031-3035	rRNA	abstract	giv	coref	21-21[165_0]
21-20	3036-3038	is	_	_	_	_
21-21	3039-3042	the	abstract[165]	giv[165]	ana	21-42[0_165]
21-22	3043-3047	most	abstract[165]	giv[165]	_	_
21-23	3048-3056	abundant	abstract[165]	giv[165]	_	_
21-24	3057-3065	cellular	abstract[165]	giv[165]	_	_
21-25	3066-3069	RNA	substance|abstract[165]	giv|giv[165]	coref	21-36[167_0]
21-26	3070-3074	type	abstract[165]	giv[165]	_	_
21-27	3075-3076	,	_	_	_	_
21-28	3077-3082	which	_	_	_	_
21-29	3083-3092	typically	_	_	_	_
21-30	3093-3101	accounts	_	_	_	_
21-31	3102-3105	for	_	_	_	_
21-32	3106-3111	about	quantity[166]	new[166]	_	_
21-33	3112-3114	80	quantity[166]	new[166]	_	_
21-34	3115-3116	%	quantity[166]	new[166]	_	_
21-35	3117-3119	of	quantity[166]	new[166]	_	_
21-36	3120-3123	the	quantity[166]|substance[167]	new[166]|giv[167]	_	_
21-37	3124-3129	total	quantity[166]|substance[167]	new[166]|giv[167]	_	_
21-38	3130-3133	RNA	quantity[166]|substance[167]	new[166]|giv[167]	_	_
21-39	3134-3135	,	_	_	_	_
21-40	3136-3140	from	_	_	_	_
21-41	3141-3146	which	_	_	_	_
21-42	3147-3150	one	abstract	giv	coref	22-6
21-43	3151-3154	can	_	_	_	_
21-44	3155-3165	reasonably	_	_	_	_
21-45	3166-3172	assume	_	_	_	_
21-46	3173-3177	that	_	_	_	_
21-47	3178-3187	oxidative	abstract[169]	giv[169]	_	_
21-48	3188-3194	damage	abstract[169]	giv[169]	_	_
21-49	3195-3197	to	abstract[169]	giv[169]	_	_
21-50	3198-3207	ribosomes	abstract[169]|object	giv[169]|new	_	_
21-51	3208-3210	in	_	_	_	_
21-52	3211-3214	all	abstract[171]	giv[171]	_	_
21-53	3215-3220	these	abstract[171]	giv[171]	_	_
21-54	3221-3233	pathological	abstract[171]	giv[171]	_	_
21-55	3234-3244	conditions	abstract[171]	giv[171]	_	_
21-56	3245-3249	must	_	_	_	_
21-57	3250-3252	be	_	_	_	_
21-58	3253-3263	widespread	_	_	_	_
21-59	3264-3265	.	_	_	_	_

#Text=Studies that focused specifically on rRNA confirmed it to be a major target of the 8-oxo-G modification in patients with AD and mild cognitive impairment , a condition that often precedes AD .
22-1	3266-3273	Studies	abstract	new	_	_
22-2	3274-3278	that	_	_	_	_
22-3	3279-3286	focused	_	_	_	_
22-4	3287-3299	specifically	_	_	_	_
22-5	3300-3302	on	_	_	_	_
22-6	3303-3307	rRNA	abstract	giv	ana	22-8
22-7	3308-3317	confirmed	_	_	_	_
22-8	3318-3320	it	abstract	giv	_	_
22-9	3321-3323	to	_	_	_	_
22-10	3324-3326	be	_	_	_	_
22-11	3327-3328	a	abstract[175]	new[175]	_	_
22-12	3329-3334	major	abstract[175]	new[175]	_	_
22-13	3335-3341	target	abstract[175]	new[175]	_	_
22-14	3342-3344	of	abstract[175]	new[175]	_	_
22-15	3345-3348	the	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
22-16	3349-3356	8-oxo-G	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
22-17	3357-3369	modification	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
22-18	3370-3372	in	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
22-19	3373-3381	patients	abstract[175]|abstract[176]|person[177]	new[175]|giv[176]|giv[177]	_	_
22-20	3382-3386	with	abstract[175]|abstract[176]|person[177]	new[175]|giv[176]|giv[177]	_	_
22-21	3387-3389	AD	abstract[175]|abstract[176]|person[177]|abstract	new[175]|giv[176]|giv[177]|giv	coref	22-32
22-22	3390-3393	and	abstract[175]|abstract[176]|person[177]	new[175]|giv[176]|giv[177]	_	_
22-23	3394-3398	mild	abstract[175]|abstract[176]|person[177]|abstract[179]	new[175]|giv[176]|giv[177]|new[179]	_	_
22-24	3399-3408	cognitive	abstract[175]|abstract[176]|person[177]|abstract[179]	new[175]|giv[176]|giv[177]|new[179]	_	_
22-25	3409-3419	impairment	abstract[175]|abstract[176]|person[177]|abstract[179]	new[175]|giv[176]|giv[177]|new[179]	_	_
22-26	3420-3421	,	abstract[175]|abstract[176]|person[177]	new[175]|giv[176]|giv[177]	_	_
22-27	3422-3423	a	abstract[175]|abstract[176]|person[177]|abstract[180]	new[175]|giv[176]|giv[177]|new[180]	_	_
22-28	3424-3433	condition	abstract[175]|abstract[176]|person[177]|abstract[180]	new[175]|giv[176]|giv[177]|new[180]	_	_
22-29	3434-3438	that	_	_	_	_
22-30	3439-3444	often	_	_	_	_
22-31	3445-3453	precedes	_	_	_	_
22-32	3454-3456	AD	abstract	giv	_	_
22-33	3457-3458	.	_	_	_	_
